Remedent, Inc. (REMI)
USD 0.04
(14.29%)
USD 0.04
(14.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 726.13 Thousand USD | -7.92% |
| 2023 | 788.59 Thousand USD | 8.1% |
| 2022 | 729.49 Thousand USD | 19.43% |
| 2021 | 610.8 Thousand USD | -50.01% |
| 2020 | 1.22 Million USD | -29.65% |
| 2019 | 1.73 Million USD | -16.61% |
| 2018 | 2.08 Million USD | -7.64% |
| 2017 | 2.25 Million USD | 15.91% |
| 2016 | 1.94 Million USD | -12.78% |
| 2015 | 2.23 Million USD | -5.68% |
| 2014 | 2.36 Million USD | -28.72% |
| 2013 | 3.31 Million USD | -58.33% |
| 2012 | 7.96 Million USD | -5.25% |
| 2011 | 8.4 Million USD | 22.24% |
| 2010 | 6.87 Million USD | -23.37% |
| 2009 | 8.97 Million USD | 36.38% |
| 2008 | 6.57 Million USD | 39.1% |
| 2007 | 4.72 Million USD | -29.41% |
| 2006 | 6.69 Million USD | 109.18% |
| 2005 | 3.2 Million USD | 52.32% |
| 2004 | 2.1 Million USD | 12.81% |
| 2003 | 1.86 Million USD | -12.34% |
| 2002 | 2.12 Million USD | 149.34% |
| 2001 | 852.65 Thousand USD | -26.85% |
| 2000 | 1.16 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 285.73 Thousand USD | 56.83% |
| 2024 FY | 726.13 Thousand USD | -7.92% |
| 2024 Q1 | 142.33 Thousand USD | -26.85% |
| 2024 Q2 | 115.87 Thousand USD | -18.59% |
| 2024 Q3 | 182.19 Thousand USD | 57.24% |
| 2023 Q4 | 194.57 Thousand USD | -9.39% |
| 2023 FY | 788.59 Thousand USD | 8.1% |
| 2023 Q3 | 214.74 Thousand USD | -12.67% |
| 2023 Q2 | 245.89 Thousand USD | 84.35% |
| 2023 Q1 | 133.38 Thousand USD | 0.0% |
| 2022 FY | 729.49 Thousand USD | 19.43% |
| 2021 FY | 610.8 Thousand USD | -50.01% |
| 2021 Q2 | 147.53 Thousand USD | 3.83% |
| 2021 Q3 | 194.65 Thousand USD | 31.94% |
| 2021 Q1 | 142.09 Thousand USD | -60.57% |
| 2020 Q4 | 360.38 Thousand USD | 24.04% |
| 2020 Q3 | 290.53 Thousand USD | 7.31% |
| 2020 Q2 | 270.73 Thousand USD | -9.79% |
| 2020 Q1 | 300.12 Thousand USD | -41.24% |
| 2020 FY | 1.22 Million USD | -29.65% |
| 2019 Q2 | 341.74 Thousand USD | -29.67% |
| 2019 Q4 | 510.77 Thousand USD | 2.94% |
| 2019 Q3 | 496.16 Thousand USD | 45.19% |
| 2019 FY | 1.73 Million USD | -16.61% |
| 2019 Q1 | 485.9 Thousand USD | -10.0% |
| 2018 Q2 | 527.23 Thousand USD | 16.92% |
| 2018 Q3 | 564.65 Thousand USD | 7.1% |
| 2018 Q4 | 539.87 Thousand USD | -4.39% |
| 2018 Q1 | 450.93 Thousand USD | -50.41% |
| 2018 FY | 2.08 Million USD | -7.64% |
| 2017 FY | 2.25 Million USD | 15.91% |
| 2017 Q2 | 464.26 Thousand USD | 9.92% |
| 2017 Q3 | 459.03 Thousand USD | -1.13% |
| 2017 Q4 | 909.26 Thousand USD | 98.08% |
| 2017 Q1 | 422.38 Thousand USD | -35.49% |
| 2016 FY | 1.94 Million USD | -12.78% |
| 2016 Q1 | 354.8 Thousand USD | -35.18% |
| 2016 Q4 | 654.77 Thousand USD | 33.1% |
| 2016 Q2 | 443.97 Thousand USD | 25.13% |
| 2016 Q3 | 491.93 Thousand USD | 10.8% |
| 2015 Q2 | 604 Thousand USD | -0.01% |
| 2015 Q4 | 547.33 Thousand USD | 15.19% |
| 2015 Q3 | 475.16 Thousand USD | -21.33% |
| 2015 Q1 | 604.03 Thousand USD | -9.75% |
| 2015 FY | 2.23 Million USD | -5.68% |
| 2014 Q2 | 539.74 Thousand USD | 4.43% |
| 2014 Q3 | 639 Thousand USD | 18.39% |
| 2014 FY | 2.36 Million USD | -28.72% |
| 2014 Q1 | 516.84 Thousand USD | -27.63% |
| 2014 Q4 | 669.32 Thousand USD | 4.74% |
| 2013 Q3 | 882.87 Thousand USD | 8.58% |
| 2013 FY | 3.31 Million USD | -58.33% |
| 2013 Q4 | 714.13 Thousand USD | -19.11% |
| 2013 Q2 | 813.1 Thousand USD | -10.42% |
| 2013 Q1 | 907.64 Thousand USD | -33.22% |
| 2012 Q2 | 2.49 Million USD | 18.08% |
| 2012 Q3 | 1.99 Million USD | -20.1% |
| 2012 Q4 | 1.35 Million USD | -31.84% |
| 2012 FY | 7.96 Million USD | -5.25% |
| 2012 Q1 | 2.11 Million USD | -11.94% |
| 2011 Q3 | 2.12 Million USD | 9.31% |
| 2011 FY | 8.4 Million USD | 22.24% |
| 2011 Q1 | 1.93 Million USD | -2.55% |
| 2011 Q2 | 1.94 Million USD | 0.63% |
| 2011 Q4 | 2.4 Million USD | 12.9% |
| 2010 Q2 | 1.47 Million USD | -7.63% |
| 2010 Q4 | 1.98 Million USD | 8.63% |
| 2010 FY | 6.87 Million USD | -23.37% |
| 2010 Q1 | 1.59 Million USD | -27.82% |
| 2010 Q3 | 1.82 Million USD | 24.0% |
| 2009 Q3 | 2.4 Million USD | 2.38% |
| 2009 FY | 8.97 Million USD | 36.38% |
| 2009 Q4 | 2.2 Million USD | -8.02% |
| 2009 Q1 | 2.01 Million USD | -9.35% |
| 2009 Q2 | 2.34 Million USD | 16.19% |
| 2008 Q3 | 1.95 Million USD | 45.02% |
| 2008 Q1 | 942.74 Thousand USD | -4.85% |
| 2008 FY | 6.57 Million USD | 39.1% |
| 2008 Q4 | 2.22 Million USD | 14.11% |
| 2008 Q2 | 1.34 Million USD | 42.68% |
| 2007 Q4 | 990.82 Thousand USD | -11.14% |
| 2007 FY | 4.72 Million USD | -29.41% |
| 2007 Q3 | 1.11 Million USD | -9.51% |
| 2007 Q2 | 1.23 Million USD | -11.38% |
| 2007 Q1 | 1.39 Million USD | 12.97% |
| 2006 Q4 | 1.23 Million USD | -51.95% |
| 2006 FY | 6.69 Million USD | 109.18% |
| 2006 Q1 | 955.93 Thousand USD | -2.11% |
| 2006 Q2 | 1.18 Million USD | 24.09% |
| 2006 Q3 | 2.56 Million USD | 115.92% |
| 2005 Q3 | 956.1 Thousand USD | 50.35% |
| 2005 FY | 3.2 Million USD | 52.32% |
| 2005 Q2 | 635.93 Thousand USD | 0.37% |
| 2005 Q1 | 633.61 Thousand USD | -15.45% |
| 2005 Q4 | 976.56 Thousand USD | 2.14% |
| 2004 Q4 | 749.41 Thousand USD | 25.27% |
| 2004 Q1 | 373.5 Thousand USD | -50.21% |
| 2004 Q2 | 381.19 Thousand USD | 2.06% |
| 2004 FY | 2.1 Million USD | 12.81% |
| 2004 Q3 | 598.22 Thousand USD | 56.93% |
| 2003 Q1 | 360.24 Thousand USD | -50.9% |
| 2003 FY | 1.86 Million USD | -12.34% |
| 2003 Q4 | 750.23 Thousand USD | 109.35% |
| 2003 Q3 | 358.36 Thousand USD | -9.24% |
| 2003 Q2 | 394.83 Thousand USD | 9.6% |
| 2002 Q4 | 733.69 Thousand USD | 32.63% |
| 2002 FY | 2.12 Million USD | 149.34% |
| 2002 Q1 | 362.5 Thousand USD | 76.14% |
| 2002 Q2 | 476.64 Thousand USD | 31.49% |
| 2002 Q3 | 553.2 Thousand USD | 16.06% |
| 2001 FY | 852.65 Thousand USD | -26.85% |
| 2001 Q2 | 102.68 Thousand USD | -64.8% |
| 2001 Q3 | 234.68 Thousand USD | 128.55% |
| 2001 Q4 | 205.81 Thousand USD | -12.3% |
| 2001 Q1 | 291.71 Thousand USD | 0.0% |
| 2000 FY | 1.16 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | 74.64% |
| Ansell Limited | 495.5 Million USD | 99.853% |
| Ansell Limited | 495.5 Million USD | 99.853% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | 99.123% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | 58.045% |
| Psykey, Inc. | 1.21 Million USD | 40.161% |
| ConvaTec Group Plc | 910.31 Million USD | 99.92% |
| ConvaTec Group Plc | 872.5 Million USD | 99.917% |
| Encision Inc. | 3.77 Million USD | 80.774% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -412.043% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -560.536% |
| Innovative MedTech Inc. | 6.09 Million USD | 88.094% |
| LifePoint, Inc. | 7.42 Million USD | 90.219% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | 88.563% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | 15.072% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Reflect Scientific, Inc. | 1.06 Million USD | 31.735% |
| SmileDirectClub, Inc. | 517 Million USD | 99.86% |
| Sector 10, Inc. | 39.84 Thousand USD | -1722.443% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 99.989% |
| SheerVision, Inc. | 2.33 Million USD | 68.857% |
| United Health Products, Inc. | 2.42 Million USD | 70.075% |
| Vasamed, Inc. | 4.67 Million USD | 84.461% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | 71.655% |
| Yubo International Biotech Limited | 1.25 Million USD | 42.273% |